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Abstract
Background: Shwachman-Diamond Syndrome (SDS) is a hereditary disease caused by mutations in the SBDS gene. SDS is
clinically characterized by pancreatic insufficiency, skeletal abnormalities and bone marrow dysfunction. The hematologic
abnormalities include neutropenia, neutrophil chemotaxis defects, and an increased risk of developing Acute Myeloid
Leukemia (AML). Although several studies have suggested that SBDS as a protein plays a role in ribosome processing/
maturation, its impact on human neutrophil development and function remains to be clarified.
Methodology/Principal Findings: We observed that SBDS RNA and protein are expressed in the human myeloid leukemia
PLB-985 cell line and in human hematopoietic progenitor cells by quantitative RT-PCR and Western blot analysis. SBDS
expression is downregulated during neutrophil differentiation. Additionally, we observed that the differentiation and
proliferation capacity of SDS-patient bone marrow hematopoietic progenitor cells in a liquid differentiation system was
reduced as compared to control cultures. Immunofluorescence analysis showed that SBDS co-localizes with the mitotic
spindle and in vitro binding studies reveal a direct interaction of SBDS with microtubules. In interphase cells a perinuclear
enrichment of SBDS protein which co-localized with the microtubule organizing center (MTOC) was observed. Also, we
observed that transiently expressed SDS patient-derived SBDS-K62 or SBDS-C84 mutant proteins could co-localize with the
MTOC and mitotic spindle.
Conclusions/Significance: SBDS co-localizes with the mitotic spindle, suggesting a role for SBDS in the cell division process,
which corresponds to the decreased proliferation capacity of SDS-patient bone marrow CD34
+ hematopoietic progenitor
cells in our culture system and also to the neutropenia in SDS patients. A role in chromosome missegregation has not been
clarified, since similar spatial and time-dependent localization is observed when patient-derived SBDS mutant proteins are
studied. Thus, the increased risk of myeloid malignancy in SDS remains unexplained.
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Introduction
Shwachman-Diamond Syndrome (SDS; also known as Shwach-
man-Diamond-Bodian Syndrome) was first described in
1964[1,2]. The symptoms of this rare, hereditary disease include
pancreatic insufficiency, skeletal abnormalities including metaph-
yseal dysostosis and bone marrow (BM) failure[1,2]. The most
prominent hematological symptom is neutropenia, (lowered
peripheral blood neutrophil cell count), which is observed in most
patients, while in 30–40% of the SDS patients also other blood cell
deficiencies, like anemia (lowered red blood cell counts) and
thrombocytopenia (lowered platelet counts), were observed[3–5].
Intriguingly, SDS patients have a highly increased risk of
developing myelodysplasia and/or acute myeloid leukemia
(MDS/AML) at young age[6].
In 2001, the genetic defect of SDS was mapped to the
centromeric region of chromosome 7 and in 2003 the defect was
narrowed down to a single gene, which was tentatively named the
Shwachman-Bodian-Diamond Syndrome (SBDS) gene[7,8]. In 90% of
the SDS patients mutations in the SBDS gene were identified and
this has provided the molecular basis for investigations into the
underlying mechanisms defective in SDS[7]. The two most
common mutations in the SBDS gene are 183–184TA.CT and
258+2T.C [4,7,9,10], which are located in SBDS exon 2 and
intron 2. These mutations result in a premature stop-codon
(K62X) and a splice-defect that causes a frameshift resulting in a
premature stopcodon (C84fsX3), respectively. It has been
reported that SDS patients have residual, low levels of SBDS
expression due to a very low, but correct residual splicing of the
258+2T.C SBDS transcript[11–13]. To date, there are no
reports confirming expression of truncated SBDS proteins in SDS
patients, although it can be expected that low levels of these
truncated proteins are produced since SBDS mutant mRNA
expression can be readily detected. Low level SBDS protein
expression in SDS patients is in line with the studies with Sbds-
deficient mice and cells, which demonstrated that SBDS is crucial
for cellular viability [14] and that complete absence of SBDS
expression is incompatible with life.
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clarified, although several elegant studies have shown its
involvement in RNA and/or ribosome processing and matura-
tion[15–18]. Molecular analysis of other bone marrow failure
syndromes, like Blackfan-Diamond anemia and dyskeratosis
congenita, have revealed that in these disorders genes encoding
ribosomal or related proteins are mutated. This underlines the
idea that ribosomes and translational-related processes are
important for proper bone marrow function[19,20]. Most
interestingly, Nucleophosmin (NPM1), a frequently mutated gene in
leukemia, which encodes for a multifunctional nucleolar protein
implicated in both ribosome biogenesis and centrosome duplica-
tion, was recently shown to interact with SBDS[15,21]. This
SBDS-nucleophosmin interaction would support the accepted
concept of a RNA/ribosome processing defect in SDS.
At the cellular level, several lines of evidence indicate that SBDS
plays a pivotal role in cell viability and/or proliferation. SBDS was
shown to be widely expressed, with highest expression levels in
highly proliferative cell types[7,14]. More recently, Austin et al.
have shown that SBDS is located at the mitotic spindle of primary
human bone marrow stromal cells[12]. Moreover, their studies
revealed that SDS patient cells (EBV B-cells and fibroblasts) are
more prone to genomic instability[12].
Consistent with the observation of lowered peripheral blood
neutrophil cell counts in SDS patients are studies with mouse
primary granulocytic precursor cells and the 32D cell line which
revealed highest SBDS expression levels in the progenitor
cells[22,23]. Knock-down of SBDS expression in 32D cells
resulted in reduced cell proliferation, but normal neutrophil
differentiation[23]. In contrast, in primary mouse hematopoietic
progenitors, decreased SBDS expression levels resulted in
impaired differentiation, but had no effect on proliferation[22].
Despite these studies in mouse neutrophilic cells and in human
bone marrow (BM) stromal cells, the exact role of SBDS in human
neutrophil development, remains to be established.
Here we show that SBDS expression is downregulated during
neutrophil differentiation in the human myeloid leukemia cell line
PLB-985 and in clinically relevant human primary CD34
+
hematopoietic progenitor cord blood differentiation cultures. We
show that SBDS co-localizes with the microtubules and centro-
some of the mitotic spindle and to some extent with the
microtubule organizing centre (MTOC) in interphase cells in
neutrophilic cells. A direct interaction of SBDS with tubulin was
shown in an in vitro microtubule binding assay. Most interestingly,
we observed that neutrophil differentiation and proliferation in
liquid cultures of SDS BM progenitors is hampered as compared
to control BM hematopoietic progenitors. These data correlate
with our previous studies revealing a dramatic decrease in BM
granulocyte-macrophage progenitor (CFU-GM) activity in SDS
patients[4] and with studies by others in mouse cells[22,23].
Altogether, our data indicate a role for SBDS in the cell division in
human myeloid progenitor cells, which may provide an explana-
tion for the observed neutropenia and leukemia in SDS.
Materials and Methods
Blood cells cell culture and transfections
Peripheral blood and bone marrow aspirates were obtained
after informed written consent from healthy controls or SDS
patients (for additional data and mutation analysis, see Table S1).
The study was approved by the Medical Ethics Committee of the
Academic Medical Centre (AMC) in Amsterdam and in
accordance with the Declaration of Helsinki. PBMCs and
neutrophils were isolated as described[4].
Myeloid PLB-985 and HL-60 cells were cultured in RPMI with
10% FCS/penicillin (200 mg/ml)/streptomycin/4 mM L-gluta-
mine. PLB-985 cells were differentiated with 0.5% dimethylfor-
mamide (DMF; Sigma) for 5–7 days. HeLa, U2OS and Cos-7 cells
were cultured in IMDM supplemented with 10% FCS/200 mg/ml
penicillin/streptomycin/4 mM L-glutamine. For transfections
Fugene6 Reagent (Roche Diagnostics, Almere, The Netherlands)
was used according to manufacturers’ instructions.
Hematopoietic CD34
+ progenitor cells were isolated and
cultured as described[24]. Briefly, Hematopoietic CD34
+ progen-
itor cells were isolated with MACS (Miltenyi Biotec, Bergisch
Gladbach, Germany) from BM aspirates or Cord Blood after
Ficoll PaquePLUS (GE Healthcare, Chalfont St. Giles, UK)
separation yielding a CD34
+ cell purity after MACS separation of
85–95%. Cells were cultured in IMDM with 10% FCS/penicillin
(200 mg/ml)/streptomycin/4 mM L-glutamine/50 mM b-mercap-
toethanol. Cells were seeded at a concentration of 0.1–0.3610
6
cells/ml and were supplemented with SCF, Flt-3, GM-CSF, G-
CSF and IL-3 at the start of the culture. From day 7 onwards cells
were supplemented only with G-CSF. Every 3 days fresh medium
was added and cells were resuspended at a concentration of
0.5610
6 cells/ml. At several time points cell counts were
determined and cytospins were made for morphological analysis.
After 17 days of culture, cells were analyzed for CD11b expression
by FACS with FITC-conjugated CD11b (Sanquin Reagents,
Amsterdam, The Netherlands).
Functional tests
NADPH-oxidase activity was assessed as hydrogen peroxide
release determined by an Amplex Red kit (Molecular Probes
Breda, The Netherlands). Cells (0.25610
6/mL) were stimulated
with zymosan (1 mg/mL) or serum-treated zymosan (STZ; 1 mg/
mL) or PMA (100 ng/mL), in the presence of Amplex Red
(0.5 mM) and horseradish peroxidase (1 U/mL). Fluorescence was
measured at 30-sec intervals for 30 min with the HTS7000+ plate
reader. Maximal slope of H2O2 release was assessed over a 2-min
interval, as described previously[4].
Intracellular calcium measurements were performed upon Fluo-
3 loading (Molecular Probes, Breda, The Netherlands) for 30
minutes at 37uC and tested for intracellular calcium mobilization
at a cell concentration of 224610
6 cells/ml, according to the
protocol described previously for neutrophils[4].
SBDS cloning and antibody generation
Full length SBDS was PCR-amplified from leukocyte cDNA with
the following primers: SBDS forward 59-GAGATCGGATCCTC-
GATCTTCACCCCCACC-39 and reverse 59-GAGATCGTC-
GACTCATTCAAATTTCTCATCTCCT-39. The PCR product
wasdirectionally cloned withBamH1and Sal1 into the pGEX-6P-1
vector (Amersham Pharmacia Biotech, Roosendaal, The Neder-
lands) to generate a GST-SBDS fusion protein and sequence
verified. Recombinant GST-SBDS protein was produced and
purified. The GST-tag was removed with PreScission protease and
recombinant full length SBDS was used to generate a polyclonal
antibody by immunization in rabbits (Eurogentec, Herstal,
Belgium). For overexpression studies SBDS was directionally cloned
into pEGFP-C1 (Clonetech, Leusden, The Netherlands) vector or
into pCDNA3 vector (Invitrogen Breda, The Netherlands)
containing a HA-tag[25].
Immunization
Human SBDS was cloned, expressed and purified for the
immunization of two different rabbits at Eurogentec according to
standard procedures (Herstal, Belgium). Two booster immuniza-
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containing sera were recognizing SBDS without major differences
in Western blotting and immunofluorescence staining, either used
as pure sera or after protein-A purification. Whole polyclonal
rabbit serum from one of the rabbits was used for the Western
blotting and immunofluorescence studies shown.
RNA isolation
RNA was isolated with Nucleospin RNA isolation system
(Macherey-Nagel, Duren, Germany) according to manufacturers’
instructions, as mentioned in Material and Methods. cDNA was
generated with Superscript III system (Invitrogen Breda, The
Netherlands) according to manufacturers’ instructions.
Western Blotting
HeLa and Cos-7 cells were lysed with 20 mM Tris-HCl pH7.4/
135 mM NaCl/1.5 mM MgCl2/1%TritonX-100/10%glycerol
and human leukocytes were lysed in Laemlli sample buffer.
Proteins were separated with SDS-PAGE and blotted to PVDF
membranes (Biorad, Veenendaal, The Nederlands). Blots were
blocked with non-fat milk, incubated with primary antibodies
overnight at 4uC, followed by HRP-conjugated secondary
antibodies. Proteins were visualized by enhanced chemilumines-
cence detection (Pierce Biotechnology, Rockford, USA). Antibod-
ies used: HA (Y11, Santa Cruz, USA), 12CA5 monoclonal (a kind
gift from B.Burgering), beta-actin (AC-15; Sigma, St.Louis, USA);
a-tubulin (DM1a; Sigma), SBDS polyclonal antibody (see above).
Immunofluorescence
Cells were fixed with 4% paraformaldehyde/PBS and stained as
described[25]. Secondary antibodies were Alexa488 or Alexa543-
conjugated (Molecular Probes, Breda, The Netherlands) and DNA
was stained with TO-PRO-3 iodide (Molecular Probes). Pictures
were made with a Zeiss Axiovert 100 M confocal microscope with
Zeiss 65x oil objective and processed with LSM 510 software.
RNA expression analysis
RNA isolated with Nucleospin RNAII system (Macherey-Nagel,
Duren, Germany) and cDNA was generated with SuperscriptIII
reverse transcriptase (Invitrogen, Carlsbad, USA) according to
manufacturers’ instructions. Quantitative RT-PCR was performed
as described[26] with the following SBDS primers: forward 59-
AGATAGAACGTGCTCACATGAGGC-39, and reverse 59-GG-
TGTCATTCAAATTTCTCATGTC-39. Glucuronidase primers
were used as normalization control.
Quantative RT-PCR
Intron-spanning primers were designed to specifically amplify
cDNA and exclude amplification of genomic DNA, yielding
products of 100 bp for glucuronidase (GUS). The following primers
were used: glucuronidase (GUS): forward primer, 59-GAAAA-
TATGTGGTTGGAGAGCTCATT-39 and reverse primer, 59-
CCGAGTGAAGATCCCCTTTTTA-39.
Amplification by PCR was performed on a LightCycler
instrument (Roche, Almere, The Netherlands), with software
version 3.5. The reaction was performed with LightCycler
FastStart DNA MasterPLUS SYBR Green I (Roche). The
annealing temperature used for all primers was 60uC. For
amplification, the following LightCycler protocol was used. Taq
polymerase was activated by hot-start for 10 minutes at 95uC; next
the template was amplified for 40 cycles of (5 seconds at 95uC, 30
seconds at 60uC, 15 seconds at 72uC). SYBR green fluorescence
was measured at the end of each cycle at 72uC. At the end of 40
cycles, melting curve analysis was performed to confirm PCR
product specificty.
Tubulin binding assay
BL21 bacteria transfected with pGEX-6P-1-SBDS were used to
produce recombinant GST-SBDS protein, which was purified
with Glutathione Sepharose 4 Fast Flow beads (Amersham
Pharmacia Biotech). The GST-tag was removed with PreScission
Protease according to the manufacturers’ instruction (GE
Healthcare) and SBDS protein was dialyzed against 80 mM
Hepes, 1 mM EGTA, 1 mM MgCl2 and supplemented with
0.02% Triton X-100. SBDS protein was pre-cleared at 100.000 g
for 20 minutes at 4uC and used in our microtubule binding protein
spin-down assay according to manufacturers’ instructions (Cyto-
skeleton, Denver, USA). Protein fractions were separated on SDS-
PAGE and Coomassie stained.
Statistics
For the comparison of mRNA concentrations as well as for
hematopoietic CD34
+ progenitor growth the analysis was
performed according to the non-parametric Mann-Whitney-U
test to determine statistical significance. For the distribution of
cellular differentiation in BM cultures were also tested in a non-
parametric manner. Cellular fractions are interdependent (totaling
100%) and were analyzed as 4-to-2 table, comparing the 4
different differentiation stages as separate categories between
controls and patients (Chi-square test). For the statistical analyses
we have used SPSS.15.0.1 software. In general, a p-value ,0.05
was considered statistically significant.
Results
SBDS antibody generation
In order to investigate SBDS protein expression, we generated a
polyclonal antibody by immunizing rabbits with full length SBDS
protein. Western blot analysis showed that the antibody recognizes
the transiently expressed HA-tagged SBDS full length protein at
the expected molecular mass of 30–34 kD (Fig. 1A) and the
endogenously expressed SBDS protein of approximately 30 kD
(indicated by the arrow head) in Cos-7 cells. Also immunofluo-
rescence stainings with the SBDS antibody on GFP-SBDS-FL
transfected Cos-7 cells (Fig. 1B) showed overlapping staining
patterns. To further characterize the antibody, we performed
Western blot analysis for several transiently expressed GFP-tagged
SBDS isoforms in Hela cells (Fig. 1C). As shown in Fig. 1D, our
antibody recognizes the GFP-SBDS-FL and GFP-SBDS-C84
protein, but not the GFP-SBDS-K62 protein. Furthermore, we
observed that our polyclonal antibody also recognizes the C-
terminal part of the SBDS protein (Fig. 1D). Thus our anti-SBDS
polyclonal antibody recognizes the SBDS C-terminus and the
peptide sequence between amino acids K63 and C84, but
definitely not the SBDS N-terminus.
SBDS expression is down-regulated during neutrophil
differentiation
Most SDS patients have lowered numbers of peripheral blood
neutrophils, suggesting that the process of neutrophil proliferation
and/or differentiation is disturbed at some stage. Since mature
peripheral blood neutrophils express relatively low levels of SBDS
(not shown), we speculated that SBDS is playing a (more)
prominent role during the early stages of neutrophil differentia-
tion. In order to substantiate this idea, we monitored the
expression of SBDS during neutrophil differentiation.
SBDS & Myeloid Differentiation
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were differentiated towards neutrophil-like cells based on mor-
phological (Fig. 2A) and functional parameters, including NADPH
oxidase activity and C5a receptor function (Fig.|S1). Quantitative
RT-PCR analyses revealed that SBDS mRNA levels decreased
during neutrophil differentiation. In the myeloid progenitors we
detected 1.7–1.8 fold higher SBDS mRNA expression as
compared to differentiated neutrophil-like cells (Fig. 2B). Similar
data on SBDS mRNA downregulation over time were observed in
the original HL-60 myeloid cell line differentiated into neutrophil-
like cells (n=3; data not shown), confirming the data in PLB-985,
which represents a subclone of the HL-60 cell line.
In line with the SBDS mRNA downregulation, we also observed
that the SBDS protein levels decreased during PLB-985 neutrophil
differentiation (Fig. 2C). Similar to the HeLa cells, immunofluo-
rescence staining for SBDS localization in PLB-985 cells revealed
that SBDS protein is localized prominently to the nucleus with a
lower extent of staining in the cytoplasm (Fig. 2D). Interestingly,
distinct perinuclear SBDS enrichment in these PLB-985 cells was
also observed (see also below).
To extend these findings, we employed a human hematopoietic
progenitor CD34
+ in vitro liquid neutrophil differentiation
system[24] for studying SBDS expression. As revealed by
morphological analysis of May-Gru ¨nwald-Giemsa stained cells,
these cells differentiated over a period of 18-21 days towards
neutrophilic cells (Fig. 3A). In line with the results from the PLB-
985 cells, we observed a 2.5–5 fold higher SBDS RNA expression
level in the CD34
+ progenitor cells (Fig. 3B). Thus, SBDS
expression is relatively high in myeloid progenitors and is down-
regulated during human neutrophil differentiation in both a
myeloid cell line as well as in primary hematopoietic progenitor
CD34
+ cord blood cells. To examine the SBDS subcellular
localization we performed SBDS immunostainings (Fig. 3C).
Highest SBDS levels were detected in the nucleus and lower levels
in the cytoplasm in these hematopoietic progenitors, including the
typical perinuclear localization (indicated with arrow) observed at
all stages of differentiation (Fig. 3C).
SBDS co-localizes with microtubule organizing center
and the mitotic spindle
In the above described cultures of the differentiating hemato-
poietic progenitor cells we noted that SBDS was located at fiber-
like structures and/or the centrosomes near the segregating
chromosomes (Fig. 3C). To further investigate the apparent co-
localization of SBDS and the mitotic spindle, we stained the
human HeLa cell line for a-tubulin and SBDS. In mitotic HeLa
cells, we observed endogenously expressed SBDS at the mitotic
spindle including the centrosomes (Fig. 4A, top panel). In
interphase cells, SBDS was perinuclear enriched and co-localized
with a central tubulin structure, also known as microtubule-
organizing center (MTOC) (Fig. 4A, bottom panel). Identical
results were obtained for GFP-SBDS-FL and HA-SBDS-FL
overexpressed proteins in HeLa and in Cos-7 cells (not shown).
Similar to what we observed in HeLa cells, cord blood-derived
CD34
+ hematopoietic progenitor cells that were differentiated
towards neutrophilic cells revealed co-localization of SBDS with
the centrosomes of the mitotic spindle (Fig. 4B, top panel). The
perinuclear SBDS enrichment co-localized with the MTOC in
interphase hematopoietic cells (Fig. 4B, bottom panel). While in
the hematopoietic progenitors the MTOC region as stained by a-
tubulin appears as a distinctive, small organelle, this appears as a
more diffuse region, including also organelles like the Golgi
apparatus, in HeLa cells and other non-hematopoietic cell lines
tested thus far.
Figure 1. Generating SBDS Antibody. To test specificity of our
SBDS antibody we overexpressed GFP- or HA-tagged SBDS in HeLa or
Cos-7 cells (A) Western blotting shows that the anti-HA antibody
recognizes a 30–34 kD protein in HA-SBDS-FL transfected Cos-7 cells. In
a duplicate blot we show that our SBDS antibody recognizes specifically
a 30–34 kD protein in HA-SBDS transfected cells. Moreover, we
detected an approximately 30 kD band, which represents the
endogenous SBDS. (B) Immunostaining with our SBDS antibody shows
that GFP-SBDS expression (green; top picture) and endogenous stained
SBDS (red; middle picture) coincides in Cos-7 cells (bottom picture). (C)
Schematic overview GFP-SBDS constructs used for transient transfec-
tion followed by Western blotting analysis. The grey, white and black
regions indicate the three main SBDS protein regions, namely an N-
terminal FYSH domain, a central helix-turn-helix motif and the C-
terminal common fold which has homology with a RNA-Recognition
Motif (RRM). (D) Western blot analysis for several GFP-SBDS protein
isoforms transiently expressed in HeLa cells. GFP staining (top panel)
shows that these constructs are expressed at expected molecular
weight and staining with our SBDS antibody shows that the antibody
recognizes GFP-SBDS-FL, R219, C84 and the N-terminally truncated
SBDS isoforms (GFP-SBDS D1–65, D1–75 and D1–85), but not GFP-SBDS-
K62. Protein standard indicates protein size as indicated (56 kD, 36 kD
and 28 kD, respectively)
doi:10.1371/journal.pone.0007084.g001
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neutrophil differentiation. (A) PLB-985 cells were cultured for several
days in the presence of 0.5% DMF to induce differentiation. May-
Gru ¨nwald-Giemsastainingofcytospins ofdifferentiatingPLB-985cells.(B)
Representative quantitative RT-PCR analysis shows that SBDS mRNA
expression decreases 1.8 fold with PLB-985 neutrophil differentiation
(n=5), showing the mean6SEM. (C) Western blot analysis for SBDS
expressing levels and actin as a protein loading control in undifferenti-
ated (day 0) and differentiating (day 3–7) PLB-985 cells shows that SBDS
protein expression decreases during neutrophil differentiation (represen-
tative for n=5 independent cellular differentiation experiments). (D)
Immunofluorescence staining for SBDS shows that SBDS localizes
prominently to the nucleus (counterstained with propidium iodide) and
to lower extent in the cytoplasm. A prominent perinuclear SBDS-enriched
structure (indicated with the arrow head) was detected in PLB-985 cells.
doi:10.1371/journal.pone.0007084.g002
Figure 3. SBDS expression is downregulated during human
cord blood CD34
+ neutrophil differentiation. Human CD34
+ cord
blood cells were differentiated towards neutrophils with a cocktail of
cytokines over a period of 18–21 days. (A) May-Gru ¨nwald-Giemsa
staining on differentiating CD34
+ cells shows that these cells are
acquiring morphological characteristics of neutrophilic cells during the
culture. (B) Representative quantitative RT-PCR analysis shows that
SBDS mRNA expression decreases 5-fold with human cord blood
neutrophil differentiation (n=3; mean6SEM). (C) Immunofluorescence
staining for SBDS in differentiating cord blood hematopoietic
progenitor and neutrophilic cells shows that SBDS protein is localized
predominantly in the nucleus and to a lower extent in the cytoplasm. In
all cells a prominent SBDS-enrichment is observed in the perinuclear
region (indicated with arrow). In mitotic cells, we observed that SBDS is
localized at the mitotic spindle and/or centrosomes during the
anaphase of mitosis (right panel).
doi:10.1371/journal.pone.0007084.g003
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been observed. The two most common mutations introduce
premature stopcodons due to a point mutation (K63X) and a
splice defect (C84fsX3). Despite these mutations, SDS patients
have been reported to have low levels of SBDS expression due
correct residual splicing of the 258+2T.C SBDS transcript
causing the C84fsX3 mutation [11–13]. Besides low level full
length SBDS protein expression, it can be assumed that also these
truncated proteins are expressed at (very) low levels in SDS
patients.
To investigate whether these truncated SBDS proteins could
potentially co-localize with the mitotic spindle and possibly disrupt
proper spindle function and, as a result, the cell division process,
we overexpressed GFP and HA-tagged SBDS-K62 and SBDS-
C84 in HeLa cells and other cell lines. Although 5- to 10-fold
lower levels of expression were obtained for these truncated SBDS
proteins compared to the full-length SBDS protein (data not
shown), we observed that, similar to the full-length protein, the
mutant SBDS-K62 and SBDS-C84 proteins co-localized with the
mitotic spindle in the cell types (Fig. 4C; and data not shown).
To further investigate the interaction of SBDS with microtu-
bules, we purified recombinant full-length SBDS (Fig. 4D; left
panel) and performed an in vitro microtubule protein binding assay.
In the absence of microtubules, SBDS remained in the soluble
fraction, while in the presence of microtubules we observed that a
significant fraction of approximately 10% of the SBDS protein co-
purified with the microtubules in the pellet fraction, indicating a
direct interaction of SBDS with microtubules. Thus, SBDS and
SBDS-patient protein isoforms co-localize with the mitotic spindle
and/or centrosomes in both HeLa cells, other adherent cell types
as well as in human hematopoietic cells. Also, we observed a direct
interaction of the full length SBDS protein with microtubules.
Together, our data suggest that SBDS is playing a role in some
microtubule and/or centrosome-related function, since SBDS
interacts with in vitro microtubules and co-localizes in vivo with
microtubule structures in both mitotic as well as interphase cells.
SBDS plays a role in proliferation of BM myeloid
progenitors
High SBDS expression levels in myeloid progenitors, combined
with the observation that SBDS co-localizes with the mitotic
spindle, suggested that SBDS could play a role in the proliferation
of developing myeloid progenitor cells. Previous studies have
shown that SDS BM cells have decreased granulocyte-macro-
phage progenitor (CFU-GM) activity[4]. However, due to
technical limitations these studies could not quantitatively address
the proliferation rate of the progenitor cells nor analyze the
different stages of neutrophil differentiation stages within these
cultures. To examine in a more quantitative manner the impact of
SBDS deficiency on the neutrophil differentiation and prolifera-
tion process, we employed a liquid neutrophil differentiation
system. Control and SDS patient BM CD34
+ hematopoietic
progenitor cells were cultured in this in vitro differentiation system
and cellular proliferation and differentiation was monitored over a
period of 17 days.
During the first week of SDS BM progenitor expansion we
observed on average 10-fold expansion in the number of cells,
while in control cultures we observed a 16.5-fold expansion in cell
number on average (Fig. 5A). This difference became even more
dramatic after 2 weeks of culture in which we observed a 27-fold
expansion in cell number for SDS BM progenitors, whereas in the
control cultures the cell number was increased 52-fold.
To examine whether the CD34
+ hematopoietic progenitor
progenitors in this differentiation culture system actually differen-
Figure 4. SBDS co-localizes with the MTOC and the mitotic
spindle. Endogenously expressed SBDS co-localizes with the mitotic
spindle and/or centrosomes (top panel) and the MTOC area (bottom
panel) in (A) HeLa cells (n=8) and in (B) cord blood CD34
+ cells (n=3).
(C) Overexpressed HA-SBDS-C84 localizes to the mitotic spindle in U2OS
cells (n=5). (D) Recombinant expressed SBDS was used as a ligand in a
microtubule-binding protein spin-down assay. Right panel shows a
Coomassie-stained gel with 5 mg of the purified SBDS protein with a
molecular weight of 30 kD. Left panel shows a Coomassie- stained gel
with SBDS protein incubated in the presence or absence of
microtubules, as indicated by tubulin staining. In the absence of
microtubules, the SBDS protein remains in the soluble fraction (s) and in
the presence of 0.16 nM taxol-stabilized microtubules, a small, but
significant fraction of the SBDS protein co-precipitates with microtu-
bules in the pellet (p) fraction. Representative result of 5 independent
experiments.
doi:10.1371/journal.pone.0007084.g004
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for CD11b at the end stage of the cultures (i.e. day 17). CD11b is a
marker expressed by macrophages and by differentiating neutro-
phils from the myelocyte stage onwards[27]. In control BM
cultures we observed 81% CD11b
+ and in the SDS BM culture
78% CD11b
+ cells, indicating that the percentage of early myeloid
progenitors is similar (Fig. 5B). To analyze the neutrophil
differentiation status in more detail, we stained cells with May-
Gru ¨nwald Giemsa (Fig. 5C) and scored the amount of early
progenitors (promyelocytes and myeloblasts), intermediately dif-
ferentiated cells (metamyelocytes) and more terminally differenti-
ated cells (metamyelocytes, band and segmented neutrophils)
based on morphological characteristics on day 17 of culture
(Fig. 5D). This revealed that SDS BM differentiation cultures
contain a 1.9-fold reduction of terminally differentiated cells and a
1.6-fold increase of intermediately differentiated cells as compared
to control cultures at day 17. Additionally, SDS cultures contain
slightly increased percentages of macrophages and decreased
percentages of immature progenitors (p,0.03). Thus, besides a
decrease in cell growth, the SDS BM differentiation cultures also
revealed a subtle but significant change in differentiation status.
Discussion
SBDS is widely expressed in several organs and cell types.
However, clinical manifestations in SDS patients are largely
restricted to the pancreas and myeloid cells. Previous studies had
already shown that in human SDS BM granulocyte-macrophage
progenitor (CFU-GM) activity is dramatically decreased as
compared to control BM cells, clearly indicating defects in the
hematopoietic progenitor compartment[4,28]. However, to date
no studies have addressed the role of SBDS and the neutrophil
differentiation defect in primary human cells in a more detailed
fashion. The data presented here, indicate that SBDS expression
levels decrease during human neutrophil differentiation, indicating
that SBDS plays its most prominent role in myeloid progenitors as
Figure 5. SBDS plays a role in myeloid progenitor proliferation. BM CD34
+ cells were differentiated towards neutrophils and monitored at
several stages for proliferation and differentiation. (A) Average fold induction of cell numbers from 5 independent SDS and 3 independent control BM
CD34
+ differentiation cultures. Control BM cultures show an overall significantly higher fold induction in the cell number as compared to SDS patient
cells. Fold induction was calculated within each experiment by dividing the number of cells in the culture at each time point by the number of cells
that was seeded at day 0. Both for controls and SDS patients 0.1520.5610
4 cells were seeded. Thereafter, the average fold was calculated. Error bars
indicate SEM (Statistical analysis according to Mann Witney U testing, p=0.014). (B) FACS analysis at day 17 shows that the percentage of CD11b
+
cells in the SDS and control cultures is approximately 80% (control n=3; SDS patient n=2). (C) Representative May-Grunwald-Giemsa stained cells of
control or SDS patient BM cultures at various days of the culture (control n=3; SDS patient n=5). (D) Bars indicate the average percentage of cells of
the indicated differentiation status at day 17 of the culture. SDS BM differentiation cultures (dark bars) show less terminally differentiated neutrophils
as compared to the control culture (light bars). However, the percentage of intermediately differentiated (myelocytic) cells and the percentage of
macrophages was (slightly) increased in SDS patient cultures (n=3 for control and n=4 for SDS patient. Per experiment 196–232 cells were
examined. 462, Chi-square test, p,0.03). May-Gru ¨nwald-Giemsa stained cells were morphologically analyzed and scored by two independent
persons in a blind fashion.
doi:10.1371/journal.pone.0007084.g005
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revealed that the differentiation capacity of SDS BM hematopoi-
etic progenitor CD34
+ progenitors is slightly impaired as
compared to control progenitor cells in our in vitro liquid BM
cultures. Additionally, the cell growth of SDS BM progenitors is
significantly decreased. Our observations are consistent with the
previously observed decrease in granulocyte-macrophage progen-
itor (CFU-GM) activity in SDS BM as compared to controls, as
well as with the observed lowered peripheral blood neutrophil cell
counts in SDS patients. Recently, two studies regarding the role of
SBDS in mouse neutrophil differentiation were published by
Yamaguchi et al. and Rawls et al., and they showed that lowering
Sbds expression in murine hematopoietic progenitor cells or
myeloid cell lines resulted in decreased myeloid cell growth and/
or decreased differentiation[22,23]. Similar to our studies in
human cells, Yamaguchi et al. showed that in mouse 32D cells
SDBS expression levels are down-regulated upon neutrophil
differentiation[23]. Additionally, they observed that cell growth
in these Sbds knock-down cultures was lowered as compared to
control cultures. The cell growth deficit was attributed to increased
apoptosis in these Sbds knock-down cells. Consistent with this, we
also observed a slightly increased percentage of apoptotic cells at
day 17 in the SDS BM cultures (6.4% of the SDS cells versus 3.0%
in the control cultures; n=3; data not shown).
Rawls et al. did not report any difference in cell growth or
apoptosis in primary murine Sbds knock-down cells, but observed a
neutrophil differentiation deficit[22] similar to our observations in
the human BM hematopoietic progenitor CD34
+ neutrophil
differentiation cultures in SDS patients. In both Rawls’ and our
studies, intermediate differentiated cells were increased at the
expense of terminally differentiated cells (i.e. segmented and band
neutrophils). The similarities between our study and both of the
murine myeloid cell studies confirm the requirement of SBDS
during the neutrophil differentiation and proliferation process in
both mice and humans and corresponds well to the clinical
observation of neutropenia in SDS patients.
Our data show that human SBDS co-localizes with microtu-
bules and centrosomes in both interphase and mitotic cells. This
observation reveals a possible regulatory role for SBDS in
proliferation and/or chromosome segregation. Cell division
defects caused by defective SBDS function, such as incorrect
chromosome distribution over the two daughter cells, can
potentially result in aneuploidy and contribute to chromosome
instability. This can ultimately result in an increased risk to
develop malignancy, such as the observed highly increased risk of
SDS patients to develop AML. Our studies are consistent with the
recently published studies by Austin et al. who reported that SBDS
co-localizes with the mitotic spindle in bone marrow stromal and
skin fibroblast cell lines [12].
Austin et al. have reported that in SDS patient cells, a higher
percentage of multipolar spindles can be detected during the cell
division process and that this resulted in genomic instability, as
determined by flow cytrometric DNA content analyses in these
SDS patient cells[12]. This is an intriguing observation, since
fibroblasts are not known to behave abnormal in SDS patients and
the only malignant derangement in SDS patients leads to acute
myeloid leukemia (AML). Moreover, solid tumors have thus far
not been reported in SDS. In limited analyses of SDS and control
BM hematopoietic and lymphoid proliferation and differentiation
studies we have not observed any multipolar spindles in mitotic
cells. It is unclear whether too few cells were analyzed in our
studies or whether the difference in cell type, culture or analysis
methods used in our and their studies contributes to this
discrepancy.
In addition to our studies in primary human SBDS deficient
cells, we have employed a model system in which we overex-
pressed either GFP- or HA-tagged full-length SBDS or patient-
derived SBDS mutant protein isoforms (i.e. SBDS-K62 and
SBDS-C84) in human cell lines in order to study the effect of these
truncated SBDS proteins. We did not observe clear effects on the
overall integrity of the microtubule cytoskeleton or on mitotic
spindle structure (CO unpublished data). Additionally, U2OS cells
transfected with GFP-SBDS-full length, GFP-SBDS-C84 or GFP-
SBDS-K62 that were selected for expression and cultured over a
period of 41-70 days did not reveal genomic instability (i.e. .4n
DNA content), as determined by flow cytometric DNA content
analysis (CO unpublished data). Nevertheless, preliminary single
cell studies revealed that SBDS full length or SDS-patient derived
protein isoform overexpression does result in longer cell cycle
length and mitotic abnormalities at low frequency, suggesting that
SBDS protein expression levels are important for correct cell
division (CO unpublished data). These data indicate that
overexpression of full-length and patient-derived SDS proteins
does not necessarily result in genomic instability that is detectable
at cell population level, but that individual cells can be affected in
their cell division process. A small percentage of cells in which
chromosomal missegregation results in a growth or survival
advantage could potentially result in the development of leukemia,
as observed in SDS patients. To further address the role of SBDS
in the cell division process, more detailed studies are required in
relevant human cellular model systems in which endogenous
SBDS expression is reduced to levels observed in SDS patients and
truncated SBDS proteins are examined for their effect on the
chromosome segregation and cell division process.
According to our findings, SBDS co-localizes with the mitotic
spindle and the MTOC in primary granulocytic progenitors,
lymphocyte blasts and various cell lines. Moreover, we show that
SBDS can interact directly with microtubules in an in vitro
microtubule binding assay. This is an interesting finding since the
MTOC is involved in many cellular processes, including
cytoplasmic organization, intracellular transport, cell shape and
polarity regulation and chromosome segregation. For these
functions, the microtubules and many associating proteins in
these complexes, require correct spatial and temporal organization
to allow proper localization and dynamics of the MTOC and the
microtubules for maintaining cellular viability and integri-
ty[29,30]. It is clear that abnormalities in the centrosomes, the
core of the MTOC, might contribute to chromosome instability
and tumor development[29]. Currently, the exact role of SBDS
microtubule regulation/organization is unclear. It was recently
shown that RNA and several RNA-binding proteins are required
for mitotic spindle formation[31], and therefore the RNA-binding
properties of SBDS might be involved in its microtubule-related
function.
Important questions that remain to be answered relate to the
role of SBDS in the regulation of microtubule assembly or
dynamics, and the putative cell-type specificity of this function. In
preliminary experiments, we observed an intact microtubule
network in SDS-patient neutrophils (Fig.S2), which argues against
a general role for SBDS in microtubule assembly. Further
characterization of the SBDS domain(s) involved in the interaction
with microtubules as well as the identification of additional
interacting proteins is also required to understand this at the
molecular level.
Taken together, there may be doubts about the exact biological
effect of SBDS on spindle formation and subsequent risk of
chromosome segregation defects. Nevertheless, in agreement with
the findings of Austin et al.[12], we show the co-localization of
SBDS & Myeloid Differentiation
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tagged SBDS in cell lines. Also we show a direct interaction of
SBDS with microtubules. Our data strongly implicate a role for
SBDS in the process of chromosome segregation and/or the cell
division process in neutrophils. This is especially interesting in light
of the highly increased risk of SDS patients to develop AML.
Furthermore, our data might have implications for unraveling the
underlying mechanisms that contribute to AML in general.
Supporting Information
Figure S1 Functional analysis of differentiated PLB-985 cells.
PLB-985 cells that are undifferentiated or differentiated for 6 days
with 0.5% DMF were tested for functional neutrophilic properties,
such as oxidative burst capacity and the expression of functional
chemo-attractant receptors. Differentiated HL-60 cells, which are
similar to PLB-985 cells, have been reported to express the
receptors for C5a and fMLP[32]. Hence, we tested differentiated
PLB-985 cells for their ability to generate an oxidative burst and to
induce a calcium-influx after stimulation with chemo-attractants.
(A) Results of an NADPH oxidase assay to measure oxidative burst
activity of undifferentiated and differentiated PLB-985 cells.
Undifferentiated cells do not respond with an oxidative burst to
zymosan, serum-treated zymosan (STZ) or PMA. Differentiated
PLB-985 cells respond to STZ and PMA with an oxidative burst.
(B) Differentiated PLB-985 cells were loaded with the fluorescent
intracellular Calcium detecting dye, Fluo3-AM. During a time
course measurement we stimulated cells with 10 nM C5a or 1 M
fMLP and changes in the intracellular calcium levels were
determined. Differentiated cells respond with a change in
intracellular calcium levels upon exposure of C5a, but not fMLP,
showing that these cells express a functional C5a receptor.
Expression of the fMLP receptor is a characteristic of the last
stages of differentiation. The observation that these cells do not
express a functional fMLP receptor, indicates that the cells are not
completely differentiated. In undifferentiated PLB-985 cells no
response to either C5a or fMLP was detected (not shown).
Found at: doi:10.1371/journal.pone.0007084.s001 (2.77 MB TIF)
Figure S2 Microtubule analysis in SDS-patient and control
neutrophils. Peripheral Blood neutrophils from SDS patients and
healthy controls were isolated and resuspended in Hepes complete
medium (132mM NaCl, 20mM Hepes, 6mM KCL, 1mM
MgSO4, 1.2mM K2HPO4, 1mM CaCl2, 5mM Glucose, 2.5%
human albumin (Cealb; Sanquin reagents)) and seeded on
fibronectin-coated coverslips (Fibronectin from Sigma) and
allowed to attach to the fibronectin substrate for 30 minutes.
Cells were fixed with 4% paraformaldehyde/PBS and processed
for immunofluorescence staining as described in material and
methods. Pictures were made with a Zeiss LSM510 microscope
with Zeiss 65x oil objective and processed with LSM 510 software.
Pictures are derived from 2 independent experiments.
Found at: doi:10.1371/journal.pone.0007084.s002 (1.88 MB TIF)
Table S1 Clinical information of SDS patient and heathy
controls. This table provides clinical information of the SDS
patients and heathy controls that provided bone marrow aspirates
that were used in this study.
Found at: doi:10.1371/journal.pone.0007084.s003 (0.03 MB
DOC)
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